GW Pharmaceuticals PLC- (NASDAQ:GWPH) Upgraded by Zacks Investment Research to “Buy”

Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a hold rating to a buy rating in a research report released on Friday morning, Zacks.com reports. They currently have $182.00 target price on the biopharmaceutical company’s stock.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

Other equities analysts also recently issued research reports about the company. JPMorgan Chase & Co. upgraded GW Pharmaceuticals PLC- from a market perform rating to an outperform rating in a report on Wednesday, May 8th. Oppenheimer downgraded GW Pharmaceuticals PLC- from an outperform rating to a market perform rating and set a $195.00 target price on the stock. in a report on Wednesday, May 8th. Guggenheim reiterated a buy rating and issued a $222.00 target price (up previously from $186.00) on shares of GW Pharmaceuticals PLC- in a report on Tuesday, May 7th. CIBC upgraded GW Pharmaceuticals PLC- from a market perform rating to an outperform rating in a report on Tuesday, May 7th. Finally, ValuEngine downgraded GW Pharmaceuticals PLC- from a buy rating to a hold rating in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the stock. GW Pharmaceuticals PLC- presently has an average rating of Buy and an average target price of $203.91.

NASDAQ GWPH opened at $151.31 on Friday. The business’s 50-day moving average is $168.39. The company has a current ratio of 7.81, a quick ratio of 7.19 and a debt-to-equity ratio of 0.03. The firm has a market cap of $4.70 billion, a P/E ratio of -14.33 and a beta of 2.25. GW Pharmaceuticals PLC- has a 1 year low of $90.14 and a 1 year high of $196.00.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.48) by $0.80. The company had revenue of $39.20 million for the quarter, compared to the consensus estimate of $12.32 million. GW Pharmaceuticals PLC- had a negative return on equity of 45.75% and a negative net margin of 458.79%. The firm’s quarterly revenue was up 1189.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.12) EPS. On average, research analysts forecast that GW Pharmaceuticals PLC- will post -5.41 earnings per share for the current fiscal year.

In related news, COO Christopher J. Tovey sold 64,800 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $14.61, for a total value of $946,728.00. Following the completion of the sale, the chief operating officer now owns 67,303 shares of the company’s stock, valued at approximately $983,296.83. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Julian S. Gangolli sold 671,928 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $14.84, for a total value of $9,971,411.52. Following the completion of the sale, the insider now directly owns 510,352 shares of the company’s stock, valued at approximately $7,573,623.68. The disclosure for this sale can be found here. In the last three months, insiders sold 1,047,660 shares of company stock valued at $15,647,815. 3.60% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. US Bancorp DE boosted its position in GW Pharmaceuticals PLC- by 0.6% during the first quarter. US Bancorp DE now owns 11,683 shares of the biopharmaceutical company’s stock worth $1,969,000 after purchasing an additional 75 shares during the period. Oppenheimer Asset Management Inc. boosted its position in GW Pharmaceuticals PLC- by 14.9% during the first quarter. Oppenheimer Asset Management Inc. now owns 601 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 78 shares during the period. Brandywine Oak Private Wealth LLC boosted its position in GW Pharmaceuticals PLC- by 6.0% during the first quarter. Brandywine Oak Private Wealth LLC now owns 1,435 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 81 shares during the period. Envestnet Asset Management Inc. boosted its position in GW Pharmaceuticals PLC- by 4.8% during the second quarter. Envestnet Asset Management Inc. now owns 2,014 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 92 shares during the period. Finally, Advisory Services Network LLC boosted its position in GW Pharmaceuticals PLC- by 23.1% during the fourth quarter. Advisory Services Network LLC now owns 511 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 96 shares during the period. 78.87% of the stock is owned by institutional investors and hedge funds.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Read More: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.